Streetwise Reports' Article Archives — Current Month (12)

Is the Trend Turning for This Psychedelic Stock? (04/19/2021)

Technical analyst Clive Maund charts Delic Inc. and explains why he considers the stock attractive at this point.


Merck Selects Rapidly Growing Psychedelic Medicine Company as Key Research Site (04/16/2021)

Novamind runs clinics, research sites and therapeutic retreats and is positioning itself for expansion.


Health Tech Company Acquiring Ontario Health Management Firm, Its Largest Transaction Ever (04/16/2021)

A Research Capital Corp. report discusses CloudMD Software & Services' acquisition of Oncidium, "one of Canada's leading health management companies."


Ardelyx to Receive $5M Milestone Payment as Japan Partner Initiates Phase 3 (04/15/2021)

Ardelyx Inc. shares traded 11% higher after Kyowa Kirin Co. Ltd., its collaborative partner in Japan, initiated four Phase 3 clinical trials of tenapanor for treatment of hyperphosphatemia.


Biotech Company Acquires Therapeutics Firm, Gains 'Gem' in the Portfolio (04/14/2021)

Dawson James Securities advised it is maintaining its "Buy" rating after Sorrento Therapeutics announced the acquisition of ACEA Therapeutics for $38 million in stock.


Novocure Shares Climb 50% on Acceleration of Phase 3 Lung Cancer Trial (04/13/2021)

Novocure Ltd. shares reached a new 52-week high after the company reported an update from its Phase 3 Pivotal LUNAR trial of tumor treating electrical fields in non-small cell lung cancer.


Affimed NV Shares Rise 20% on Initial Data from Phase 1 R/R CD30-Positive Lymphoma Trial (04/09/2021)

Affimed NV shares reached a new 52-week high price after the company presented initial data from a Phase 1 trial of its AFM13 that shows potential to help NK cells target and destroy cancer cells.


Gene Therapy Restoring Light Sensitivity 'Showed Impressive Dose-Response Improvements' (04/07/2021)

Roth Capital Partners advised that Applied Genetic Technologies co-development of BS01 with Bionic Sight "validates its gene therapy capabilities."


Biopharma's Phase 2b/3 Alzheimer's Disease Trial Approved to Continue (04/07/2021)

Anavex Life Sciences' study, its drug's mechanism of action and the company's upcoming catalysts are covered in a Dawson James Securities report.


Biohaven Expects Net Revenue of $43.8 Million in Q1 for Its Migraine Medicine (04/07/2021)

Biohaven Pharmaceutical shares traded 10% higher after the company reported that in Q1/21 net product revenue for its migraine drug NURTEC ODT is estimated to be approximately $43.8 million.


Nano-X Imaging Receives Go Ahead from FDA for Single Source Digital X-Ray (04/05/2021)

Shares of Nano-X Imaging Ltd. traded 17% higher after the company reported that the FDA has granted 510(k) approval for its single source ARC digital x-ray.


United Therapeutics Shares Rise 15% as FDA Clears Pathway to Launch Tyvaso to Treat PH-ILD (04/01/2021)

United Therapeutics shares reached a new 52-week high after the firm reported that the U.S. FDA granted approval to commercially launch its TyvasoŽ Inhalation Solution to treat patients with pulmonary hypertension associated with interstitial lung disease.


More Archives

2021Mar Feb Jan

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes